Type and Crossmatch Needed Before Initiating Treatment With Daratumumab

Share this content:
Type and screen of patients prior to starting daratumumab is recommended.
Type and screen of patients prior to starting daratumumab is recommended.

Why is a type and crossmatch needed before starting patients on treatment with daratumumab (Darzalex)?

Daratumumab is a monoclonal antibody used as monotherapy or in combination with other treatments to treat multiple myeloma. The agent is targeted to CD-38, which is also expressed on red blood cells. This can cause erratic false positives in the blood antibody screening and crossmatching performed prior to a transfusion.

Although the patient's ABO and Rh blood type are not affected, detection of minor antibodies is affected. Due to the long lifespan of red blood cells, the effects of daratumumab on crossmatching can last up to 6 months after completion of therapy.

Specific techniques can be used to complete blood compatibility testing, but these can require additional time. The laboratory performing the crossmatching should also be informed in advance that the patient is on daratumumab to facilitate proper testing. Type and screen of patients prior to starting daratumumab is recommended to prevent delays in transfusion crossmatching. 

See also: Value of Type and Crossmatch Prior to Daratumumab Administration

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs